The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
DermTech develops diagnostics for skin cancer and other skin diseases, and provides molecular pathology services through its CLIA-certified lab.
Danaher has commenced its concurrent offerings of $1.35 billion of shares of its common stock and $1.35 billion of shares of its mandatory convertible preferred stock.
Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.
MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.
The business is part of Thermo Fisher's Specialty Diagnostics segment and generates about $350 million in revenues annually.
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
The company will continue to explore strategic alternatives with financial advisor Raymond James & Associates.